iVS-1 Probiotic Intervention Targeting Biological Aging in Midlife Adults
United States80 participantsStarted 2026-02-01
Plain-language summary
This study is a randomized, double-blind, placebo-controlled clinical trial designed to evaluate the effects of Bifidobacterium adolescentis (iVS-1) supplementation on biological aging markers, metabolic health, and functional health outcomes in midlife adults. The study explores whether modulation of aging-related biological pathways through the gut microbiome may influence health-related outcomes.
Who can participate
Age range40 Years ā 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Aged 40-75 years.
* BMI: 20-34.9 kg/mĀ².
* Able and willing to sign informed consent and participate for the study duration.
Exclusion Criteria:
* Chronic disease history (liver, kidney, heart).
* Current pregnancy and/or lactating.
* Colonoscopy and/or its preparation within 4 weeks of screening.
* Those who intend to have children during study period.
* Current probiotic, prebiotics and/or metabolic-altering supplement use.
* Those who are unable to cooperate with investigators and testing.
* Known history of cancer and/or ongoing cancer treatments.
* Abuse of drugs, alcohol, tobacco, nicotine and other substances.
* History of cardiac diseases: atherosclerosis, heart failure, unstable angina, stable angina, etc., and chronic hypoxic disease: emphysema, pulmonary heart disease and others related.
* History of chronic and major GI disease (pancreatitis, IBS, and IBD) and intestinal surgeries.
* Type 1 or 2 diabetes mellitus.
* Poorly controlled chronic diseases (hypertension, hyperlipidemia) that are clinically unstable.
* Vulnerable groups, including clinically ill, mentally ill, cognitively impaired, minors, and illiterate etc.
* Significant weight loss (\>20%) in prior one month.
* Conditions affecting safety or outcome integrity.